Physician profile
Shariar Borbor
NPI 1477868933
$1,392.63
in general payments reported to CMS, 2019-2025
19 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $66.99 · 2021: $145 · 2022: $82.51 · 2023: $183 · 2024: $200 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.69 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.58 | 2025 | Xifaxan |
| Cranial Technologies, INC | $140.46 | 2019-2025 | Doc Band |
| Amgen INC. | $127.95 | 2019-2025 | Repatha, Otezla |
| Sanofi Pasteur INC. | $120.79 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $91.80 | 2019-2021 | |
| Abbvie INC. | $86.79 | 2022-2025 | Qulipta |
| Lilly USA, LLC | $64.66 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Phadia US INC. | $51.35 | 2022-2024 | Immunocap |
| Glaxosmithkline, LLC. | $49.66 | 2020-2021 | |
| Organon LLC | $44.90 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $38.57 | 2025 | Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $33.06 | 2019-2021 | |
| Astellas Pharma US INC | $29.96 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $28.54 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.99 | 2024 | Eliquis |
| Hologic Sales and Service, LLC | $21.88 | 2023 | Aptima, Third Wave |
| Janssen Pharmaceuticals, INC | $17.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shariar Borbor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.